Literature DB >> 15150532

The neurotensin agonist PD149163 increases Fos expression in the prefrontal cortex of the rat.

Kimberly A Petrie1, Michael Bubser, Cheryl D Casey, M Duff Davis, Bryan L Roth, Ariel Y Deutch.   

Abstract

Dopaminergic axons innervating the prefrontal cortex (PFC) target both pyramidal cells and GABAergic interneurons. Many of these dopamine (DA) axons in the rat coexpress the peptide neurotransmitter neurotensin. Previous electrophysiological data have suggested that neurotensin activates GABAergic interneurons in the PFC. Activation of D2-like DA receptors increases extracellular GABA levels in the PFC, as opposed to the striatum, where D2 receptor activation inhibits GABAergic neurons. Because activation of presynaptic D2 release-modulating autoreceptors in the PFC suppresses DA release but increases release of the cotransmitter neurotensin, D2 agonists may enhance the activity of GABAergic interneurons via release of neurotensin. In order to determine if neurotensin can activate GABAergic interneurons, we treated rats with the peptide neurotensin agonist, PD149163, and examined Fos expression in PFC neurons. Systemic administration of PD149163 increased overall Fos expression in the PFC, but not in the dorsal striatum. PD149163 induced Fos in PFC interneurons, as defined by the presence of calcium-binding proteins, and in pyramidal cells. Pretreatment with the high-affinity neurotensin antagonist, SR48692, blocked neurotensin agonist-induced Fos expression. These data suggest that neurotensin activates interneurons in the PFC of the rat.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15150532     DOI: 10.1038/sj.npp.1300494

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  17 in total

1.  The neurotensin-1 receptor agonist PD149163 inhibits conditioned avoidance responding without producing catalepsy in rats.

Authors:  Elizabeth N Holly; Bree Ebrecht; Adam J Prus
Journal:  Eur Neuropsychopharmacol       Date:  2011-01-28       Impact factor: 4.600

Review 2.  The role of neurotensin in central nervous system pathophysiology: what is the evidence?

Authors:  Fannie St-Gelais; Claudia Jomphe; Louis-Eric Trudeau
Journal:  J Psychiatry Neurosci       Date:  2006-07       Impact factor: 6.186

3.  β-Arrestin-Biased Allosteric Modulator of NTSR1 Selectively Attenuates Addictive Behaviors.

Authors:  Lauren M Slosky; Yushi Bai; Krisztian Toth; Caroline Ray; Lauren K Rochelle; Alexandra Badea; Rahul Chandrasekhar; Vladimir M Pogorelov; Dennis M Abraham; Namratha Atluri; Satyamaheshwar Peddibhotla; Michael P Hedrick; Paul Hershberger; Patrick Maloney; Hong Yuan; Zibo Li; William C Wetsel; Anthony B Pinkerton; Lawrence S Barak; Marc G Caron
Journal:  Cell       Date:  2020-05-28       Impact factor: 41.582

4.  Response of limbic neurotensin systems to methamphetamine self-administration.

Authors:  G R Hanson; A J Hoonakker; M E Alburges; L M McFadden; C M Robson; P S Frankel
Journal:  Neuroscience       Date:  2012-01-02       Impact factor: 3.590

5.  Activation of neurotensin receptor type 1 attenuates locomotor activity.

Authors:  Chelsea A Vadnie; David J Hinton; Sun Choi; YuBin Choi; Christina L Ruby; Alfredo Oliveros; Miguel L Prieto; Jun Hyun Park; Doo-Sup Choi
Journal:  Neuropharmacology       Date:  2014-06-11       Impact factor: 5.250

6.  Repeated effects of the neurotensin receptor agonist PD149163 in three animal tests of antipsychotic activity: assessing for tolerance and cross-tolerance to clozapine.

Authors:  Shinnyi Chou; Collin Davis; Sean Jones; Ming Li
Journal:  Pharmacol Biochem Behav       Date:  2014-11-26       Impact factor: 3.533

Review 7.  Neurotensin in reward processes.

Authors:  María Luisa Torruella-Suárez; Zoe A McElligott
Journal:  Neuropharmacology       Date:  2020-02-11       Impact factor: 5.250

8.  The reversal of amphetamine-induced locomotor activation by a selective neurotensin-1 receptor agonist does not exhibit tolerance.

Authors:  David Feifel; Gilia Melendez; Rachel J Murray; Dan N Tina Tran; Michelle A Rullan; Paul D Shilling
Journal:  Psychopharmacology (Berl)       Date:  2008-06-21       Impact factor: 4.530

9.  The neurotensin-1 receptor agonist PD149163 blocks fear-potentiated startle.

Authors:  Paul D Shilling; David Feifel
Journal:  Pharmacol Biochem Behav       Date:  2008-10       Impact factor: 3.533

10.  The brattleboro rat displays a natural deficit in social discrimination that is restored by clozapine and a neurotensin analog.

Authors:  D Feifel; S Mexal; Gilia Melendez; Philip Y T Liu; Joseph R Goldenberg; Paul D Shilling
Journal:  Neuropsychopharmacology       Date:  2009-03-25       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.